CDP-Choline and Working Memory After TBI: A Neuroimaging Study

This study has been completed.
Sponsor:
Collaborators:
Information provided by (Responsible Party):
Patricia M. Arenth, University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00727246
First received: July 29, 2008
Last updated: June 10, 2013
Last verified: June 2013
  Purpose

The purpose of this study is to determine whether an investigational drug, called "CDP-Choline", improves memory in people with traumatic brain injury (TBI). To do this, we are asking for people with traumatic brain injury and people without traumatic brain injury to be a part of this study. We will compare results between each group to see if this investigational drug makes a difference with memory. We will also compare brain imaging results and information collected before and after the taking of the study medication to see if there are any differences. We hypothesize that there will be differences in brain activation patterns between individuals with TBI and healthy controls, as well as differences in performance on memory testing at baseline. We further hypothesize that, after treatment with CDP-Choline, the patterns in neuroimaging findings and cognitive testing results for individuals with TBI will more closely resemble results observed for healthy individuals. We hope that what we learn from this study will be helpful in the future treatment of individuals with head injury.


Condition Intervention Phase
Brain Injuries
Drug: CDP-Choline
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: CDP-Choline and Working Memory After TBI: A Neuroimaging Study.

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Primary Outcome Measures:
  • Follow-up neuropsychological testing Follow-up fMRI Follow-up Working memory task performance during fMRI [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Enrollment: 20
Study Start Date: March 2009
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Treatment with CDP-Choline
Drug: CDP-Choline
1000 mg CDP-Choline 2 x per day for 6 weeks.
Other Names:
  • Citicoline
  • Cytidine 5'-diphosphocholine
Placebo Comparator: 2
Treatment with Placebo
Drug: Placebo
Treatment with placebo for 6 weeks

Detailed Description:

Despite the prevalence of working memory deficits following traumatic brain injury (TBI), the scientific data regarding pharmacological treatment of this problem is limited. As deficits in working memory are known to have a significant impact on functional outcomes for individuals with TBI, further research in this area is essential in order for physicians to be able to treat this problem more effectively. The primary goal of the proposed project is to examine the efficacy of a particular pharmacological agent, CDP-Choline, in the treatment of working memory deficits following traumatic brain injury (TBI). The study sample will consist of 48 subjects: A group of 24 individuals who have sustained moderate to severe TBI, and a group of 24 healthy controls. Each group will be divided into a placebo and treatment group. The project will utilize functional Magnetic Resonance Imaging (fMRI) to investigate the cerebral neurophysiological effects of treatment with CDP-Choline. A working memory task (N-Back) will be employed during fMRI sessions. In addition, the effects of treatment with CDP-Choline on neuropsychological testing performance will also be evaluated, and the correlations between behavioral performance and neuroimaging results will be observed. We will achieve these goals by comparing baseline neuropsychological testing results as well as fMRI results, with a second set of testing and neuroimaging results obtained following 1 month of pharmacological treatment with CDP Choline or placebo. Based on our preliminary studies and the available literature, we expect to see the following: Baseline fMRI results are expected to show that individuals with TBI display altered patterns of cerebral activation during a working memory task, as compared to healthy controls. With CDP-Choline treatment, we expect TBI subjects to display fMRI laterality and dispersion patterns that more closely resemble patterns of healthy controls. In addition, we anticipate improvements in behavioral performance on both the specific working memory task (N-Back), and on traditional neuropsychological tests to be associated with CDP-Choline treatment, with greater magnitude of change on testing results for the TBI group as compared to any changes noted for the control or placebo groups. Finally, we anticipate that specific significant correlations will be observed between neuropsychological testing results and neuroimaging findings, and that the strength of these relationships will be greater for the TBI treatment group, as compared to the placebo or healthy control groups. By conducting the proposed study in this manner, we hope to provide scientific data that will allow for improved treatment, and ultimately improved functional outcomes for individuals who have sustained TBI.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

For individuals with TBI and Health Controls:

  • right hand dominant
  • English speaking
  • No history of neurological illness (for example, stroke, seizure or brain tumor.
  • No significant history of psychiatric illness (for example, schizophrenia or bipolar disorder) or current severe emotional distress.
  • No visual difficulties that would not allow for reading and following written instructions.
  • Free of alcohol or substance abuse.
  • Capable of following basic written and oral instructions.
  • Not taking certain medications that may interact with study medication or interfere with neuroimaging.
  • Be able to take medication in tablet form, or crushed and dissolved in a liquid.
  • Meet the additional criteria associated with MRI safety standards, as required by the University of Pittsburgh Department of Radiology. For example, these criteria include exclusion due to surgical placement of metal plates or electronic implants.

In addition:

Individuals with TBI must:

  • Have a specific diagnosis of a moderate to severe traumatic brain injury, which can be confirmed through review of medical records or assessments.
  • Be at least 1 year, but no more than 3 years since injury.
  • Must have significant working memory problems, as indicated by performance on a screening test.

Normal Control subjects must:

  • Perform within the normal range on a test of working memory.

Exclusion Criteria:

  • Prisoners.
  • Males with sexual partners who are planning to become pregnant during the treatment period.
  • Females who are currently pregnant or who are planning to become pregnant during the treatment period.
  • Individuals who are currently enrolled in another medication study
  • Individuals who are currently, or have previously been, treated with CDP-Choline (Citicoline) for research or clinical purposes.
  • Currently in a nursing home in the state of Pennsylvania.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00727246

Locations
United States, Pennsylvania
University of Pittsburgh, Department of Physical Medicine & Rehabilitation
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Investigators
Principal Investigator: Patricia M. Arenth, Ph.D. University of Pittsburgh
  More Information

Additional Information:
No publications provided

Responsible Party: Patricia M. Arenth, Assistant Professor, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT00727246     History of Changes
Other Study ID Numbers: PRO07020121, K23HD049626
Study First Received: July 29, 2008
Last Updated: June 10, 2013
Health Authority: United States: Federal Government
United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by University of Pittsburgh:
Traumatic Brain Injury
FMRI
Memory
Cognition
Neuropsychology

Additional relevant MeSH terms:
Brain Injuries
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Craniocerebral Trauma
Trauma, Nervous System
Wounds and Injuries
Choline
Cytidine Diphosphate Choline
Lipotropic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses
Lipid Regulating Agents
Nootropic Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on October 01, 2014